Claims
- 1. A biomolecular carrier of pharmaceuticals, comprising:
a biomolecule carrier bearing molecules that bind to a cellular adhesion molecule expressed on endothelial cell; and a pharmaceutical.
- 2. The biomolecular carrier of claim 1, wherein said molecules that bind to a cellular adhesion molecule is selected from the group consisting of antibodies, antibody fragments and ligands that bind to said cellular adhesion molecule
- 3. The biomolecular carrier of claim 1, wherein said carrier is made from a substance selected from the group consisting of biodegradable particles, liposomes, microbubbles, polymersomes, and synthetic secretory granules.
- 4. The biomolecular carrier of claim 1, wherein said cellular adhesion molecule is selected from the group consisting of ICAM-1, E-selectin, P-selectin, VCAM-1, and PECAM-1.
- 5. The biomolecular carrier of claim 1, wherein said pharmaceutical is an anti-neoplastic compound.
- 6. A method of treating a pathophysiological state in an individual in need of such treatment, comprising the steps of:
irradiating a target tissue or organ in said individual; and administering to said individual the biomolecular carrier of claim 1.
- 7. The method of claim 6, wherein said pathophysiological state is selected from the group consisting of cancer, arteriovenous malformations (AVM), macular degeneration and restenosis.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims benefit of priority of provisional patent application U.S. Ser. No. 60/239,666, filed Oct. 12, 2000, now abandoned.
FEDERAL FUNDING LEGEND
[0002] This invention was produced in part using funds obtained through a grant from the National Institutes of Health. Consequently, the federal government has certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60239666 |
Oct 2000 |
US |